Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda reports positive data from Adcetris CTCL study

Takeda reports positive data from Adcetris CTCL study

12th August 2016

Takeda and Seattle Genetics have reported new clinical data showing the effectiveness of Adcetris in the treatment of cutaneous T-cell lymphoma (CTCL).

Results from the phase III ALCANZA clinical trial have shown that the drug demonstrated a highly statistically significant improvement in the rate of objective responses lasting at least four months among patients with CD30-expressing CTCL who received prior systemic or radiation therapy.

Although it is not yet approved for the treatment of CTCL, Adcetris could be a promising new option for those affected by the disease, as the antibody-drug conjugate works by targeting CD30, which is expressed on skin lesions in approximately 50 percent of CTCL patients.

This is the first phase III randomised trial in CTCL versus an active control to demonstrate such benefits, and the results of the trial will be used to support future regulatory filings for the drug.

Dr Dirk Huebner, executive medical director for oncology at Takeda, said: "This outcome further establishes our commitment to patients living with CD30-expressing disease, and we look forward to sharing these data with regulatory authorities globally."

The drug was approved in Europe for the treatment of post-transplant Hodgkin lymphoma last month.

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.ADNFCR-8000103-ID-801823514-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.